Proteasome inhibitors are a type of medication that interfere with the activity of proteasomes.

Electra Therapeutics unveils initial study results from their active Phase 1b trial of ELA026 designed to combat secondary HLH (hemophagocytic lymphohistiocytosis)

When patients take atropine to treat gastrointestinal pain, it is easy to produce side effects of blurred vision.

Agenus Inc., an innovator in immune-modulatory cancer treatments, announced reaching its second milestone in the global licensing agreement with Bristol Myers Squibb for BMS-986442, a bispecific TIGIT antibody with improved Fc functionality.

RANKL inhibitors are drugs that target the RANKL protein, crucial in bone metabolism. The future sees potential applications in treating bone-related disorders and certain cancers.

Atara Biotherapeutics Unveils Encouraging Early Research Results for ATA3431, an Innovative Off-the-Shelf CAR Therapy Aimed at CD20 and CD19, at the 65th Annual Session of ASH.

The inducing factors of adverse drug reactions include non drug factors and drug factors.

The FDA has approved Pfizer’s review request for marstacimab, a hemophilia A/B treatment for non-inhibitor patients.

PD-1 inhibitors are drugs that target the PD-1 protein, crucial for regulating immune responses. The future of PD-1 inhibitors is promising, with potential applications in treating various types of cancer.

SystImmune and industry giant Bristol Myers Squibb have announced a partnership and licensing agreement focused on BL-B01D1, SystImmune's cutting-edge EGFRxHER3 bispecific antibody-drug conjugate.

If the drug is discontinued or tapered off too quickly, the body's regulation is disrupted, leading to functional issues, symptom resurgence, and worsened disease, known as withdrawal effects.

Oculis Reveals Initial Participant Commencement in Phase 2b RELIEF Study for Topical Anti-TNFα Agent Licaminlimab (OCS-02) Aimed at Treating Dry Eye Conditions.